Eliem Therapeutics, Inc. (ELYM) EV/EBITDA Multiple
The EV/EBITDA trading dynamics for Eliem Therapeutics (ELYM) stand at . However, the business faces uncertainty regarding clinical trials and costly development projects that may become obsolete. The company's stability relies on the development of drugs for psychiatric disorders, where patent protection promises high returns. Biotech risks are mitigated by existing capital and the search for new growth vectors, despite a heavy dependence on a couple of key drugs.
Analytical breakdowns for eliemtx.com (ELYM)
- current price and projected stock value:
- market capitalization details:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Eliem Therapeutics|ELYM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Eliem Therapeutics Inc.|ELYM - Aggregate Debt Obligations|Debts to Book Capitalization Eliem Therapeutics Inc.|ELYM - Long-Term Debt|Company Short-Term Debt Eliem Therapeutics|Quick Ratio eliemtx.com
- business earnings and investment ratios data:
ELYM - Net Profit|Expected Profit Eliem Therapeutics|ELYM - Market Cap to Net Income|Forward P/E Multiple Eliem Therapeutics Inc.|ELYM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Eliem Therapeutics Inc.|ELYM - Operating profit EBITDA|Net earnings per share for the last 12 months Eliem Therapeutics|ELYM - Earnings per share for the last four quarters|Quarterly EPS earnings growth eliemtx.com|ELYM - Expected net earnings per share growth this year|Earnings growth forecast for next year Eliem Therapeutics
- sales and revenue data:
Summary company analysis:Eliem ELYM
Eliem Therapeutics (ELYM) is scaling its search for neurological pathology treatments through laboratory robotics and AI modeling. Analyzing the company's EV/EBITDA chart, an investor can see the ratio of total enterprise value to operating profit before depreciation and amortization. A decline in this multiple signals asset undervaluation, allowing for the rapid identification of an entry point while cash flow stability is maintained.
Competitor analysis
EV/EBITDA Multiple BIIB (Biogen Corp)|Total Company Value to Operating Income Before Depreciation Ratio Neurocrine Corp (NBIX)|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Xenon Pharmaceuticals Inc.|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OMER (Omeros)|neurogene.com (NGNE) - Company Value to EBITDA|ACIU: Enterprise Value to EBITDA Ratio|VYGR - EV/EBITDA Multiple|NMRA (Neumora Therapeutics Inc) - Enterprise Value to EBITDA Ratio|SCLX: Enterprise Value to Operating Income Before Depreciation Ratio|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|Company Value to EBITDA Vistagen Therapeutics|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABOS (Acumen Pharmaceuticals Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio CRVO|Company Value to EBITDA Alterity Therapeutics Ltd ATHE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|Enterprise Value to EBITDA Ratio pepgen.com PEPG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NRXS - Company Value to EBITDA|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|Passage Bio Inc. (PASG) - Company Value to EBITDA|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NERV: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATHA: EV/EBITDA Multiple|ADXN - Total Company Value to Operating Income Before Depreciation Ratio|ALZN (Alzamend Neuro Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Cyclerion CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|Enterprise Value to EBITDA Ratio pasitheaclinics.com KTTA|Cortigent - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ATXI|BCLI: Enterprise Value to EBITDA Ratio|caratherapeutics.com - Enterprise Value to Operating Income Before Depreciation Ratio|CHRO: EV/EBITDA Multiple|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
